Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 15314172 
Castoria G, et al. (2004) Role of atypical protein kinase C in estradiol-triggered G1/S progression of MCF-7 cells. Mol Cell Biol 24, 7643-53 15314172
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S473-p - Akt1 (human)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
estrogen increase

T638-p - PKCA (human)
Orthologous residues
PKCA (human): T638‑p, PKCA (mouse): T638‑p, PKCA (rat): T638‑p, PKCA (cow): T638‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
estrogen no change compared to control

T642-p - PKCB (human)
Orthologous residues
PKCB (human): T642‑p, PKCB iso2 (human): T641‑p, PKCB (mouse): T609‑p, PKCB iso2 (mouse): T641‑p, PKCB (rat): T642‑p, PKCB iso2 (rat): T641‑p, PKCB (cow): T641‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
estrogen no change compared to control

S645-p - PKCD (human)
Orthologous residues
PKCD (human): S645‑p, PKCD (mouse): S643‑p, PKCD iso2 (mouse): S669‑p, PKCD (rat): S643‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
estrogen no change compared to control

T412-p - PKCI (human)
Orthologous residues
PKCI (human): T412‑p, PKCI (mouse): T411‑p, PKCI (rat): T412‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
estrogen increase
ICI 182,780 estrogen inhibit treatment-induced increase

S676-p - PKCT (human)
Orthologous residues
PKCT (human): S676‑p, PKCT (mouse): S676‑p, PKCT (rat): S676‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
estrogen no change compared to control

T410-p - PKCZ (human)
Orthologous residues
PKCZ (human): T410‑p, PKCZ (mouse): T410‑p, PKCZ (rat): T410‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  COS (fibroblast), MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
estrogen increase
ICI 182,780 estrogen inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Comments:  phosphorylation leads to recruitment of Ras to a multimolecular complex


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.